July 27, 2017 08:42 AM EDTUpdated 09:04 AM

Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board

Shehla Shakoor

Managing Director

→ After getting chastised by regulators in an internal FDA review of Toronto-based Intellipharmaceutics‘ $IPCI new pain drug Rexista, a panel of outside experts joined …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

In­tel­liphar­ma­ceu­tics shares crushed as FDA ex­perts snub pain drug; Mon­cef Slaoui joins Mod­er­na board

Managing Director

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board